Weekly Peptide Research Briefing - October 26 to November 2, 2026
Everything filed, reported or changed in the last seven days, in one place. Studies carry the grade they contribute, headlines link to the outlet, and every change to our own pages is listed rather than quietly applied.
Written by the Librarian every Monday from that week’s filed studies. No sponsorships, one click out.
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.
Orforglipron resulted in statistically significant weight loss in Japanese adults with obesity compared to placebo, but the clinical implications of this weight loss need further investigation.
Top-journal study · Human study · Phase 3 — the highest-scoring filing indexed this week.
Read our analysis →Studies filed
45 this week · 16 with human data · sorted by the grade they contributeOpen the research library →No significant changes in availability or access noted since the last update. · Item updates applied: 0 · Status label → Access to GLP-1 drugs remains limited · Status tone → amber
See the reasoning →The legality of compounded GLP-1 drugs remains tightly restricted following the removal from the FDA shortage list. · Item updates applied: 2 · Status label → Restricted · Status tone → red
See the reasoning →Retatrutide remains in Phase 3 development with no updates on approval status. · Item updates applied: 0 · Status label → Not approved — Phase 3 · Status tone → amber
See the reasoning →No significant changes in availability or access noted since the last update. · Item updates applied: 0 · Status label → Access to GLP-1 drugs remains limited · Status tone → amber
See the reasoning →Community pulse
Anecdotal · not evidencer/Semaglutide, r/Peptides · past 7 daysIncluded for sentiment, never as evidence: self-selected, unverified, no denominator. They do not affect any grade on this site.
Many peptides covered here are not approved for human use and are sold strictly for research. Nothing on this page is diagnosis, treatment, or a recommendation. Consult a licensed clinician before any decision about your health, and see our editorial policy and AI disclosure for how these items are sourced and summarised.